scholarly journals The Emerging Concern and Interest SARS-CoV-2 Variants

Pathogens ◽  
2021 ◽  
Vol 10 (6) ◽  
pp. 633
Author(s):  
Edyta Janik ◽  
Marcin Niemcewicz ◽  
Marcin Podogrocki ◽  
Ireneusz Majsterek ◽  
Michal Bijak

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for coronavirus disease 2019 (COVID-19) was discovered in December 2019 in Wuhan, China. Since that time, the virus has spread around the world, which resulted in an announcement of the World Health Organization (WHO), dated in March 2020, that COVID-19 was a worldwide pandemic, and since then, the world has been struggling with this disease. SARS-CoV-2, similar to other RNA viruses, continually mutates, and new variants are appearing. Among large numbers of detected SARS-CoV-2 variants, only an insignificant amount of them are able to pose a risk to public health, as they are more contagious and cause more severe conditions. The emerged variants were classified by the Centers for Disease Control and Prevention (CDC) in collaboration with SARS-CoV-2 Interagency Group (SIG) according to strictly defined pattern. Variants were classified as variants of concern, variants of interest, and variants of high consequence. In the last few months, three variants of concern (B.1.1.7, B.1.351, and P.1) and four variants of interests (B.1.526, B.1.525, B.1.427/B.1.429, and P.2) were distinguished and are essential for close monitoring. This analysis summarizes the principal information concerning SARS-CoV-2 variants, such as their infectivity, severity, mutations, and immune susceptibility.

JAMIA Open ◽  
2020 ◽  
Author(s):  
Srikar Chamala ◽  
Sherri Flax ◽  
Petr Starostik ◽  
Kartikeya Cherabuddi ◽  
Nicole M Iovine ◽  
...  

Abstract Coronavirus disease 2019, first reported in China in late 2019, has quickly spread across the world. The outbreak was declared a pandemic by the World Health Organization on March 11, 2020. Here, we describe our initial efforts at the University of Florida Health for processing of large numbers of tests, streamlining data collection, and reporting data for optimizing testing capabilities and superior clinical management. Specifically, we discuss clinical and pathology informatics workflows and informatics instruments which we designed to meet the unique challenges of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing. We hope these results benefit institutions preparing to implement SARS-CoV-2 testing.


2021 ◽  
pp. 19-23
Author(s):  
Donizete Tavares Da Silva ◽  
Priscila De Sousa Barros Lima ◽  
Renato Sampaio Mello Neto ◽  
Gustavo Magalhães Valente ◽  
Débora Dias Cabral ◽  
...  

In March 2020, the World Health Organization (1) declared COVID-19 as a pandemic and a threat to global public health (2). The virus mainly affects the lungs and can cause acute respiratory distress syndrome (ARDS). In addition, coronavirus 2 severe acute respiratory syndrome (SARSCOV2) also has devastating effects on other important organs, including the circulatory system, brain, gastrointestinal tract, kidneys and liver


2020 ◽  
Vol 11 (7) ◽  
Author(s):  
Xing Li ◽  
Ying Wang ◽  
Patrizia Agostinis ◽  
Arnold Rabson ◽  
Gerry Melino ◽  
...  

Abstract The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019. As similar cases rapidly emerged around the world1–3, the World Health Organization (WHO) declared a public health emergency of international concern on January 30, 2020 and pronounced the rapidly spreading coronavirus outbreak as a pandemic on March 11, 20204. The virus has reached almost all countries of the globe. As of June 3, 2020, the accumulated confirmed cases reached 6,479,405 with more than 383,013 deaths worldwide. The urgent and emergency care of COVID-19 patients calls for effective drugs, in addition to the beneficial effects of remdesivir5, to control the disease and halt the pandemic.


2020 ◽  
Vol 2020 (4) ◽  
Author(s):  
Abhiman Cheeyandira

Abstract Corona virus pandemic has affected all the 50 states in the USA. States such as NY, CA and WA being the most affected. According to the Centers for Disease Control and Prevention (CDC) website, as of 28 March 2020, the total number of cases in the USA is over 103 300 and number of deaths to 1668. In the coming weeks, COVID-19 rates are expected to begin skyrocketing and hit a peak in late April/May/June given lessons learned from China, Italy and others. COVID-19 has been declared a pandemic by the World Health Organization (WHO) as confirmed cases approach 575 444 patients with 26 654 deaths across over 160 countries, as of 28 March 2020. There is a lot of impact on management of the urgent and emergent cases. This article highlights the changes that are being made in delivering urgent and emergent surgical care during the pandemic.


2020 ◽  
Vol 21 (8) ◽  
pp. 2839 ◽  
Author(s):  
Ayumu Asai ◽  
Masamitsu Konno ◽  
Miyuki Ozaki ◽  
Chihiro Otsuka ◽  
Andrea Vecchione ◽  
...  

Since the infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in China during December 2019, the coronavirus disease 2019 (COVID-19) has spread on a global scale, causing the World Health Organization (WHO) to issue a warning. While novel vaccines and drugs that target SARS-CoV-2 are under development, this review provides information on therapeutics which are under clinical trials or are proposed to antagonize SARS-CoV-2. Based on the information gained from the responses to other RNA coronaviruses, including the strains that cause severe acute respiratory syndrome (SARS)-coronaviruses and Middle East respiratory syndrome (MERS), drug repurposing might be a viable strategy. Since several antiviral therapies can inhibit viral replication cycles or relieve symptoms, mechanisms unique to RNA viruses will be important for the clinical development of antivirals against SARS-CoV-2. Given that several currently marketed drugs may be efficient therapeutic agents for severe COVID-19 cases, they may be beneficial for future viral pandemics and other infections caused by RNA viruses when standard treatments are unavailable.


2009 ◽  
Vol 7 (4) ◽  
pp. 9
Author(s):  
Atresha Karra, JD ◽  
Emily Cornette, JD

This article focuses on the existing methods for tracking and restricting the spread of communicable diseases, both within United States borders and across nations. It will first describe the roles played by the United States’ Centers for Disease Control and Prevention and the World Health Organization and will then explore how communicable diseases across the world are identified and monitored. This will be followed by a discussion of US and world reporting requirements and methods. Finally, the article will discuss the tactics used by the United States to control the spread of disease.


2017 ◽  
Vol 19 (3) ◽  
pp. 144-150
Author(s):  
Evonne T Curran

This outbreak column explores the epidemiology and infection prevention guidance on tuberculosis (TB) in the UK. The column finds that, at present, national guidance leaves UK hospitals ill-prepared to prevent nosocomial TB transmission. Reasons for this conclusion are as follows: (1) while TB is predominantly a disease that affects people with ‘social ills’, it has the potential to infect anyone who is sufficiently exposed; (2) nosocomial transmission is documented throughout history; (3) future nosocomial exposures may involve less treatable disease; and (4) current UK guidance is insufficient to prevent nosocomial transmission and is less than that advocated by the World Health Organization and the Centers for Disease Control and Prevention.


2020 ◽  
Vol 23 (7) ◽  
pp. 498-502 ◽  
Author(s):  
Huda Fatima Rajani ◽  
Fatima Ahmed Alshaikh ◽  
Amir Anushiravani

A recent outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected more than 1100000 (April 5, 2020) individuals worldwide and is spreading rapidly. The virus is reported to be derived from bats and the infection was first reported in China. Similar to the severe acute respiratory syndrome and the Middle East respiratory syndrome coronaviruses, it is responsible for respiratory tract infection. Real time polymerase chain reaction and radiography are the two main diagnostic methods. Guidelines from the Center for Disease Control and Prevention and the World Health Organization (WHO) should be followed for diagnostic and precautionary measures. Treatment of the infection is still not available; however, antivirals are under clinical trials.


Author(s):  
Nur Hidayah Che Ahmat ◽  
Syafiqah Rahamat ◽  
Susan Wohlsdorf Arendt

The novel Coronavirus disease (COVID-19) first appeared in December 2019 in Wuhan, Hubei Province China before emerging in neighbouring countries in early 2020. The World Health Organization (WHO) declared COVID-19 a pandemic when the spreading of the virus started accelerating in many parts of the world and killing thousands of people. As of 22nd May 2021, there were more than 166 million confirmed cases with more than 147 million recovered and nearly 3.5 million deaths (Worldometers, n.d.). According to the WHO (2020) and Centers for Disease Control and Prevention (2020), the virus easily spreads through coughing and sneezing. Therefore, many countries implemented social distancing between individuals and various other restriction orders or recommendations (e.g., stay-at-home policies, closure of non-essential businesses) to help curb virus spread. How governments in each country reacted to control the spread of the virus appeared crucial to mitigate public health and economic impacts. Keywords: Foodservice, Hospitality, Hotel, Malaysia, Pandemic


Sign in / Sign up

Export Citation Format

Share Document